IDSA GUIDELINES Bundle (free trial)

Drug-Susceptible Tuberculosis

IDSA GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/770889

Contents of this Issue

Navigation

Page 19 of 23

20 Immunosuppressive agents Cyclosporine, tacrolimus RFB may allow concomitant use of cyclosporine and a rifamycin; monitoring of cyclosporine and tacrolimus serum concentrations may assist with dosing. Corticosteroids Monitor clinically; may require 2- to 3-fold increase in corticosteroid dose. Anticonvulsants Phenytoin, lamotrigine TDM recommended; may require anticonvulsant dose increase. Cardiovascular agents Verapamil, nifedipine, diltiazem (a similar interaction is also predicted for felodipine and nisoldipine) Clinical monitoring recommended; may require change to an alternate cardiovascular agent. Propranolol, metoprolol Clinical monitoring recommended; may require dose increase or change to an alternate cardiovascular drug. Enalapril, losartan Monitor clinically; may require a dose increase or use of an alternate cardiovascular drug. Digoxin (among patients with renal insufficiency), digitoxin TDM recommended; may require digoxin or digitoxin dose increase. Quinidine TDM recommended; may require quinidine dose increase. Mexiletine, tocainide, propafenone Clinical monitoring recommended; may require change to an alternate cardiovascular drug. eophylline eophylline TDM recommended; may require theophylline dose increase. Sulfonylurea hypoglycemics Tolbutamide, chlorpropamide, glyburide, glimepiride, repaglinide Monitor blood glucose; may require dose increase or change to an alternate hypoglycemic drug. Hypolipidemics Simvastatin, fluvastatin Monitor hypolipidemic effect; may require use of an alternate antihyperlipidemic drug. Table 8. Clinically Significant Drug–Drug Interactions Involving the Rifamycins a (cont'd) Treatment

Articles in this issue

Archives of this issue

view archives of IDSA GUIDELINES Bundle (free trial) - Drug-Susceptible Tuberculosis